Patents by Inventor Jack Lile

Jack Lile has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10947521
    Abstract: A process for producing recombinant trypsin from prokaryote host cells in high yield and high specific activity is described. In particular, a process for producing recombinant trypsin from E. coli is described.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 16, 2021
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Mark C. Sleevi, Jack Lile
  • Patent number: 10301611
    Abstract: A process for refolding recombinant chymotrypsin produced from prokaryote host cells is described. In particular, the present invention provides a process for refolding recombinant chymotrypsin produced from E. coli is described.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: May 28, 2019
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Mark C. Sleevi, Jack Lile, Bryn Grimison
  • Publication number: 20170342397
    Abstract: A process for refolding recombinant chymotrypsin produced from prokaryote host cells is described. In particular, the present invention provides a process for refolding recombinant chymotrypsin produced from E. coli is described.
    Type: Application
    Filed: November 13, 2015
    Publication date: November 30, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mark C. Sleevi, Jack Lile, Bryn Grimison
  • Publication number: 20170335308
    Abstract: A process for producing recombinant trypsin from prokaryote host cells in high yield and high specific activity is described. In particular, a process for producing recombinant trypsin from E. coli is described.
    Type: Application
    Filed: November 13, 2015
    Publication date: November 23, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mark C. Sleevi, Jack Lile
  • Patent number: 7226758
    Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.
    Type: Grant
    Filed: September 17, 1992
    Date of Patent: June 5, 2007
    Assignee: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Publication number: 20040175795
    Abstract: A novel neurotrophic factor referred to as glial derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.
    Type: Application
    Filed: January 14, 2004
    Publication date: September 9, 2004
    Applicant: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Publication number: 20020197675
    Abstract: A novel neurotrophic factor referred to as glial derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.
    Type: Application
    Filed: November 13, 2001
    Publication date: December 26, 2002
    Applicant: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Patent number: 6362319
    Abstract: A novel neurotrophic factor referred to as glial derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: March 26, 2002
    Assignee: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Patent number: 6221376
    Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified. Genes encoding GDNF have been cloned and sequenced. Methods and devices are disclosed for the delivery of GDNF using either an implantable cell which expresses human GDNF or a biocompatible semipermeable membrane containing genetically engineered cells which express and secrete the neurotrophic factor.
    Type: Grant
    Filed: September 22, 1997
    Date of Patent: April 24, 2001
    Assignee: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Patent number: 6093802
    Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: July 25, 2000
    Assignee: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Patent number: 6015572
    Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process. An implantable device containing recombinant GDNF secreting cells encapsulated in a semipermeable membrane may be used to treat nerve damage in patients suffering from disorders such as Parkinson's disease.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: January 18, 2000
    Assignee: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Patent number: 5986070
    Abstract: This invention describes processes for producing mature human members of the NGF/BDNF family of neurotrophic proteins that are fully biologically active. In addition, the gene encoding human BDNF and human BDNF are disclosed. A previously-unreported member of the NGF/BDNF family of neurotrophic proteins, NGF-3, has been identified and a portion of the gene encoding for the NGF-3 has been described.
    Type: Grant
    Filed: August 27, 1997
    Date of Patent: November 16, 1999
    Assignee: Amgen Inc.
    Inventors: Frank D. Collins, Jack Lile, Susan Becktesh, Tadahiko Kohno, Drizislav Mismer, deceased
  • Patent number: 5935795
    Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process. Antibodies to GDNF are disclosed, as well as methods for identifying members of the GDNF family of neurotrophic factors.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: August 10, 1999
    Assignee: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Patent number: 5606031
    Abstract: A process for the production of biologically active recombinant neurotrophic factor from the NGF/BDNF family is described. The process is comprised of a) constructing a synthetic neurotrophic factor gene suitable for expression in a bacterial expression system; b) the synthetic neurotrophic factor gene is expressed in a bacterial expression system; c) the neurotrophic factor is solubilized and sulfonylated; d) sulfonylated neurotrophic factor is allowed to refold in the presence of polyethylene glycol and urea; and e) biologically active neurotrophic factor is isolated and purified.
    Type: Grant
    Filed: June 27, 1994
    Date of Patent: February 25, 1997
    Inventors: Jack Lile, Tadahiko Kohno, Duane Bonam, Mary S. Rosendahl
  • Patent number: 5235043
    Abstract: This invention describes processes for producing mature human members of the NGF/BDNF family of neurotrophic proteins that are fully biologically active. In addition, the gene encoding human BDNF and processes for obtaining the same are disclosed.A previously-unreported member of the NGF/BDNF family of neurotrophic proteins, NGF-3, has been identified and a portion of the gene encoding for the NGF-3 has been described. Processes for identifying additional previously unreported members of the NGF/BDNF family are also described.
    Type: Grant
    Filed: October 9, 1990
    Date of Patent: August 10, 1993
    Assignee: Synergen, Inc.
    Inventors: Frank Collins, Susan Bektesh, Tadahiko Kohno, Jack Lile